

Pembrolizumab KEYNOTE-868/NRG-GY018

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life




QoL data pending



Serious and disabling adverse effects



Other adjustments



Long-term plateau in the PFS curve



Pembrolizumab KEYNOTE-868/NRG-GY018

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies
Therapeutic Indication: Pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. (Cohort data with dMMR)
Experimental Arm: Pembrolizumab + Carboplatin and paclitaxel
Control Arm: Carboplatin, paclitaxel, and placebo

